Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Current Leases (2019 - 2025)

Myriad Genetics (MYGN) has disclosed Current Leases for 7 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases fell 46.09% to $6.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.9 million, a 46.09% decrease, with the full-year FY2025 number at $6.9 million, down 46.09% from a year prior.
  • Current Leases was $6.9 million for Q4 2025 at Myriad Genetics, down from $7.9 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $17.8 million in Q3 2023 to a low of $6.9 million in Q4 2025.
  • A 5-year average of $13.1 million and a median of $13.4 million in 2022 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: increased 27.82% in 2023, then crashed 46.09% in 2025.
  • Myriad Genetics' Current Leases stood at $13.0 million in 2021, then increased by 8.46% to $14.1 million in 2022, then rose by 14.89% to $16.2 million in 2023, then decreased by 20.99% to $12.8 million in 2024, then plummeted by 46.09% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Current Leases are $6.9 million (Q4 2025), $7.9 million (Q3 2025), and $9.0 million (Q2 2025).